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This present study was planned to obtain an up-to-date picture of Hepatitis C virus (HCV) infection and its
genotypes distribution in Peshawar, Khyber Pakhtunkhwa, Pakistan, as well as of the relationship between
HCV genotypes and demographic and clinical parameters, and the risk factors in patients with an HCV
subtype. Samples (blood) from 1978 individuals were collected and were tested using a strip-based
method called the immunochromatographic test (ICT) for the existence of antibodies against HCV. It was
observed that 158 of the 1978 individuals (7.9%) harbored antibodies in their blood against HCV, among
which the female percentage (53.2%) was higher than that of the male (46.8%). Among the different age
groups, the highest number of incidences of HCV antibodies was found in the age group of 31e40 years
(26.6%). ICT positive samples were further screened by polymerase chain reaction (PCR) to determine the
existence of active HCV-RNA, and it was found that 6.21% (123) of the total population (1978) tested, was
positive, among which the female rate (56.91%) was observed to be higher than that of the male (43.09%).
The highest incidence recorded was in the age group of 41e50 years (33.3%). HCV RNA positive individuals
were genotyped: genotype 3a (45.5%) was dominant among the other detected genotypes, followed by 1a
(11.4%), 3b (4.9%), and 2a (4.1%). It was concluded that the highest prevalence of HCVwas found in females,
and that the dominant genotype of the screened individuals was 3a genotype.
Copyright © 2017 Institut Pertanian Bogor. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction route of transmission of HCV to the host mainly occurs throughHepatitis C is a chronic liver disease mainly caused by a dimin-
utive (50nmin size) enveloped, positive-sense, single-strandedRNA
(ssRNA) virus called Hepatitis C virus (HCV). HCV is amember of the
genus hepacivirus. It was first identified as a newviral agent causing
non-A, non-B hepatitis (Chen andMorgan 2006; Choo et al.1989). It
is a major cause of liver dysfunction leading to liver injury, cirrhosis
andhepatocellular carcinoma, and is a prominent health problemall
over theworld, especially in developing countries (Wedemeyer et al.
2014), suchas Egypt andPakistan (Averhoff et al.2012). TheprincipalGrassland Agro-ecosystems,
nology, Lanzhou University,
(T. Kumar).
nian Bogor.
r. Production and hosting by Elsblood transfusion, un-sterilized surgical instruments, dental surgi-
cal instruments, the use of illegal drugs, the sharing of daily use
things of an infected person, and acupuncture, while sexual trans-
mission and interfamilial transmission have been also reported
(Qureshi et al. 2013). Although symptoms may be not severe for
decades, approximately 20% of infected patients may suffer from
lethal liver injury and liver cancer (Imran et al. 2013). Recently, a
report on HCV infection in Pakistanwas published in 2007e2008 by
the Pakistan Medical Research Council. A total of about 47,000 in-
dividuals from the all provinces of Pakistan were screened, and the
anti-HCVwas found to be present in 4.8% of the population (Dhingra
et al. 2014). In view of the fact that the HCV genome is highly het-
erogenetic in nature, to date it has been grouped into at least six
major genotypes (genotypes 1e6), which can be further classified
into various small sub-groups world-wide (Gower et al. 2014). Ofevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Table 1. Details of primers used for genotyping, as described by Ohno et al. (1997)
Primer Sequence (5ʹe3ʹ) Expected band
size (bp)
Sc2 GGGAGGTCTCGTAGACCGTGCACCATG 441
Ac2 GAG(AC)GG(GT)AT(AG)TACCCCATGAG(AG)TCGGC
Mix1 primer
S7 AGACCGTGCACCATGAGCAC
S2a AACACTAACCGTCGCCCACAA
G1b CCTGCCCTCGGGTTGGCTA(AG) 234
G2a CACGTGGCTGGGATCGCTCC 139&190
G2b GGCCCCAATTAGGACGAGAC 337
G3b CGCTCGGAAGTCTTACGTAC 176
Mix2 primer
S7 AGACCGTGCACCATGAGCAC
G1a GGATAGGCTGACGTCTACCT 208
G3a GCCCAGGACCGGCCTTCGCT 232
G4 CCCGGGAACTTAACGTCCAT 99
G5a GAACCTCGGGGGGAGAGCAA 320
G6a GGTCATTGGGGCCCCAATGT 346
For the naming of primers, S ¼ sense; A or G ¼ antisense and C ¼ core region; the
notations 1ae6a are in accordance with the HCV genotype nomenclature proposed
by Simmonds et al. (1994). Numbering is from the authentic start codon of the open
reading frame.
2s, second-round PCR for sequencing; 2g, second-round PCR for genotyping. Pairs of
nucleotides inside parentheses denote degenerate nucleotides sequence.
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groups plays a key role in the study of geographical and de-
mographic differences, as well as in molecular epidemiology, vac-
cine development, therapeutic decision-making, and the study of
chronic HCV infection. Hence, it provides important clinical infor-
mation for health improvement planning andpolicy. The prevalence
of HCV is slightly higher than in developed countries because of the
limited availability of resources (Gul et al. 2016). Although there is a
need among the large populations of the developing world to study
the relationship of HCV bygenotypewith age, gender, route of entry
and thedurationof infection, there is currentlya lackof relevantdata
available. The aim of this present study was therefore to obtain an
up-to-date picture of the distribution of HCV infection and its ge-
notypes in Peshawar city, Khyber Pakhtunkhwa, Pakistan, as well as
to analyze the relationship between HCV genotypes and de-
mographic and clinical parameters, and to look at the risk factors
present in patients with an HCV subtype.
The hope is that this present study will also help to draw the
attention of local and foreign organizations to this important issue.
Peshawar city was decided on as a good site to conduct the research
because of the very low literacy rate in almost all of its districts, the
limited availability of health facilities, and the frequency of natural
disasters such as floods. The polymerase chain reaction (PCR)
method holds an advantage over non-PCR immunoassays such as
enzyme-linked immunosorbent assay (ELISA), recombinant immu-
noblot assay (RIBA), enzyme linked immunosorbent assay (EIA),
immunochromatographic test (ICT), and so on, being a quick and
reliable tool to diagnose, genotype and quantify active HCV RNA in
theblood.However, todate, there is noPCR-basedprevalence studies
with large sample numbers available for the population of Pakistan.
2. Materials and Methods
2.1. Sampling
This study was conducted in the Alfalah PCR Laboratory and
Research Center, Dabgari Garden capital province Peshawar, Khyber
Pakhtunkhwa, Pakistan from February 2013 to January 2015, in
which blood samples of 1978 individuals comprising 809 males and
1169 females were taken through sera and extracted. All necessary
information were gained through proper questionnaires, informed
consent and ethical approvals were taken from each infected patient
as directed by expert physician and owner of the hospital, and kept
confidential. All the individuals were categorized into age groups
10e20, 21e30, 31e40, 41e50 and over 50 years, respectively.
2.2. Initial screening
Initially, the sera were screened for the presence of anti-HCV
antibodies using a strip-based method called an ICT. For this pur-
pose, a commercially available kit (ACON®, ACON Laboratories Inc.,
San Diego, CA, USA) was used according to the protocol recom-
mended by the manufacturer. The positive samples were further
processed for molecular detection and genotyping.
2.3. PCR confirmation of HCV
From the samples that had tested positive for anti-HCV anti-
bodies, HCV RNA was extracted using a TRIzol reagent (Invitrogen,
Carlsbad, USA) following the protocol recommended by the com-
pany. The complementaryDNA (cDNA)was synthesized using gene-
specific reverse primers by reverse transcription, using Moloney
murine leukemia virus reverse transcriptase at 37C for 50minutes.
The viral RNA was confirmed through PCR using primers
(F): 50-CCCTGTGAGGAACTACTGTCTTCACGC-30, and
(R): 50-ACTCGCAAGCACCCTATCAGGCAGTAC-30,whereas the primers used for internal core region amplification
were:
Forward: 50-GAAAGCGTCTAGCCATGGCG-30 and
Reverse: 50-CACAAGGCCTTTCGCGACC-30.2.4. PCR-based identification of HCV strains
RNA from each sample was isolated by following the Ohno et al.
(1997) protocol. Reverse transcription PCR was performed for viral
cDNA generation using core gene-specific reverse primers, and
multiplex-PCR was performed for genotypes identification. Two
reaction mixtures, containing two sets of primers each, were pro-
cessed in parallel in the nested PCR (Table 1). The PCR-thermal
cycler was set to 94C for 5 minutes for pre-denaturation, fol-
lowed by denaturation at 94C for 30 seconds (30 cycles). Primer
annealing was carried out at 64C for 30 seconds; this was followed
by an extension at 72C for 30 seconds, and a final temperature of
4C for 10 minutes. The same conditions were applied for the
nested PCR; however, primer annealing was carried out at 53C.
3. Results
3.1. Initial screening
A total of 1978 individuals consisting of 809 males and 1169
females were initially screened using ICT for the presence of anti-
bodies against HCV. The results showed that 158 of the 1978 in-
dividuals (7.9%) were positive. Among the positive individuals, 74
(46.8%) were males and 84 (53.2%) were females (Figure 1).
3.2. PCR-based confirmation of active HCV
The detection of antibodies against HCV is not a reliable test for
HCV. Therefore, all anti-HCV carrying samples were confirmed for
the presence of HCV RNA using PCR (Figure 2). It was observed that
123 individuals (77.8%) tested positive for the presence of HCV RNA.
More incidences were observed in females (70; 56.91%) as
compared with males (53; 43.09%) (Figure 1).
Among the different age groups, the highest incidence of anti-
HCV antibodies (42; 26.6%) was observed in the following age
groups: 31e40 years, followed by the 21e30 years (35; 22.2%), 51
Figure 3. Age-wise distribution of the anti-HCV antibodies and HCV RNA positive.
HCV ¼ Hepatitis C virus.
Figure 1. Sex-wise distribution of the anti-HCV antibodies and HCV RNA.
HCV ¼ Hepatitis C virus.
Figure 2. Representative gel photograph of HCV amplified products. Lane 1 is negative
control, lanes 2e7 are the typical positive samples for active HCV showing expecting
220 bp band of hepatitis C virus and lane 8 represents molecular marker (1 kb).
HCV ¼ Hepatitis C virus.
T. Kumar, et al24years and above (33; 20.9%), 41e50 years (30; 19%) and 10e20 years
(18; 11.4%) (Figure 3). Similarly, the highest incidence of the pres-
ence of HCV RNAwas observed in the following age groups: 41e50
years (41; 33.3%), followed by 31e40 years (27; 22.0%), 51 years and
above (24; 19.5%), 21e30 years (20; 16.3%) and 10e20 years (11;
8.9%) (Figure 3).Figure 4. Distribution of HCV genotypes in Peshawar province. HCV ¼ Hepatitis C
virus.3.3. Distribution of HCV genotypes among different age
groups
The HCV RNA positive samples (123) were genotyped. Among
the samples tested, genotype 3a was found to be the most domi-
nant genotype, being detected in 56 of 123 individuals (45.5%)
among all the age groups. The second most dominant viralgenotype was 1a, which was detected in 14 individuals (11.4%),
followed by 3b and 2a which were detected in 6 (4.9%) and 5 (4.1%)
individuals, respectively. A total of 22 samples (17.9%) were found
with untypeable genotypes, as no genotype-specific PCR fragments
band was observed, whereas the infection of two (mixed) different
genotypes was observed in 20 individuals (16.3%) (Figure 4).4. Discussion
Viral hepatitis is alarmingly high among the general population
of Pakistan; ten million people or 6% of the total population of
Pakistan is infectedwith HCV (Raja and Janjua 2008). In this study, a
random sample was taken from the mixed population of Peshawar
city, Pakistan, including the majority Pashtun, other smaller ethnic
groups such as the Hindkowans, Dards, Chitralis and Gujjars, and
Afghan refugees. The molecular epidemiology of HCV varies by
region and in different groups of the same population (Idrees et al.
2008, Wild and Hall 2000). In our study, 6.21% prevalence of HCV
was observed, which is comparatively higher than that of Islam-
abad (5.31%) (Idrees et al. 2008), Rawalpindi (2.45%) (Masood et al.
2007), Bunir (5%) (Muhammad and Jan 2005), Multan (4.06%)
(Idrees et al. 2008), Karachi (4%e6%) (Khan et al. 2011), and lower
than that of Faisalabad (20.89%) (Ahmad et al. 2007), Mardan (9%)
(Ali et al. 2010) and Northern Areas (25.7%) (Tariq et al. 1999). This
could be due to various factors including the lack of quality health
care, poor literacy rate, low average socio-economic status, general
lack of awareness, lack of availability of suitable screening facilities,
and differences in population samples selected for the study (Shah
et al. 1997). When comparing the different age groups, we found
that the highest prevalence of HCV infection occurred among adult
men. Age has been argued to be a major factor in HCV studies, with
infection more predominant in older persons (Cozzolongo et al.
2009, Mengal et al. 2012). Our study clearly indicates the domi-
nance of genotypes 3a (45.5%) and 1a (11.4%) among the tested
population. These results validate the findings of Ahmad et al.
(2010), who reported that 59.9% and 16.5% of individuals were
infected with 3a and 1a genotypes, respectively, both these being
higher percentages than the other genotypes detected. Many
other studies have also reported that genotype 3a occurs most
frequently in Pakistan (Afridi et al. 2014, Ahmad et al. 2010). Ge-
notype 4a was not detected in our study; this genotype seems to be
very rare in Pakistan. However, Ahmad et al. (2010) isolated geno-
type 4a in a study of prevalence in Lahore, Pakistan. Other studies
reveal that genotype 4a is prevalent in theMiddle East (Abdulkarim
et al. 1998, Gower et al. 2014). Genotypes 5a and 6a were also not
isolated in our study. Acquaintance about the occurrence of
different HCV genotypes in different regions of Pakistan is
Prevalence and genotypic distribution of HCV 25considered to be an important clinical parameter for molecular
epidemiology, vaccine development, therapeutic implications and
chronic HCV infection (Ahmad et al. 2010, Ali et al. 2010). HCV is
reported to exhibit elevated levels of genetic variation. On the basis
of nucleotide sequences recuperated from HCV infected persons,
HCV is categorized into six genotypes and several subtypes (Smith
et al. 2014). These genotypes showed 30%e35% nucleotide differ-
ences in their genomes. However, these differences are not evenly
spread throughout the genome, as a very large variability is present
within the viral glycoproteins (Simmonds 2004). HCV genotypes
show a discrepancy in distribution. Genotypes 1e3 are very widely
distributed, whereas genotype 4 is more prominent in Africa and
the Middle East, genotype 5 is prominent in South Africa, genotype
6 in South East Asia and genotype 7 in Central Africa (Gower et al.
2014, Simmonds 2004).
In our study, an unknown HCV genotype was detected in 27 of
123 individuals (17.9%). Most HCV studies in Pakistan reveal the
isolation and detection of an unknown/undetermined HCV geno-
type (Ahmad et al. 2010, Ali et al. 2010, Rauf et al. 2011). In future, a
significant challenge for researchers and experts is the identifica-
tion of this/these unknown genotype(s), and the exploration of its/
their possible role in the development of Hepatitis C. This will help
to ease clinical management, the process of diagnosis, vaccine
development and other prevention measures.
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